Ocugen (NASDAQ:OCGN – Get Free Report) had its target price boosted by research analysts at Chardan Capital from $4.00 to $5.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 300.00% from the stock’s previous close.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a research report on Wednesday, April 3rd.
View Our Latest Report on Ocugen
Ocugen Trading Up 0.8 %
Institutional Investors Weigh In On Ocugen
A hedge fund recently bought a new stake in Ocugen stock. Truefg LLC purchased a new position in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 21,000 shares of the company’s stock, valued at approximately $34,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
See Also
- Five stocks we like better than Ocugen
- How to Calculate Options Profits
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Comparing and Trading High PE Ratio Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- The 3 Best Fintech Stocks to Buy Now
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.